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Abstract
Linkage analysis has the potential to localize disease genes of interest, but the choice of which subjects to select
for follow-up sequencing after identifying a linkage peak might influence the ability to find a disease gene. We
compare nine different strategies for selection of subjects for follow-up sequencing using sequence data from the
Genetic Analysis Workshop 17. We found that our more selective strategies, which included methods to identify
case subjects more likely to be affected by genetic causes, out-performed sequencing all case and control subjects
in linked pedigrees and required sequencing fewer individuals. We found that using genotype data from
population control subjects had a higher benefit-cost ratio than sequencing control subjects selected as being the
opposite extreme of the case subjects. We conclude that choosing case subjects for sequencing based on more
selective strategies can be reliable and cost-effective.
Background
The well-established genome-wide linkage analysis
method has the potential to focus the search for and
identification of genetic loci responsible for a disease or
trait. Although linkage analysis has been successfully
used to find high-penetrant rare loci for a number of dif-
ferent diseases, with the advent of high-density marker
sets, the challenges associated with linkage analysis have
limited its use somewhat. These challenges include (1)
the difficulty and cost of ascertaining large high-risk ped-
igrees, (2) shifts in general thought about whether com-
mon complex diseases are caused by common variants
(the common disease/common variant hypothesis, which
has favored association study designs) or, most recently,
by multiple rare variants [1], and (3) often the inability to
localize and identify a disease gene under a previously
established linkage peak.
I nt h i ss t u d yw ef o c u so nt h et h i r dc h a l l e n g e ,n a m e l y ,
the inability to identify a disease gene under a linkage
peak. It is possible that the choice of subjects selected for
follow-up sequencing after finding linkage evidence
influences detection of underlying genetic loci. Because
sequencing costs are still prohibitively expensive, particu-
larly for large chromosomal regions, the number of sub-
jects selected for follow-up sequencing may be limited.
Here, we explore different strategies for selecting subjects
for follow-up sequencing to identify the most reliable and
cost-effective means for choosing appropriate sequencing
candidates.
Methods
Data description
We use the mini-exome sequence data available for
Genetic Analysis Workshop 17 (GAW17). Eight extended
pedigrees are simulated based on gene dropping from the
pedigree founders’ single-nucleotide polymorphism
(SNP) genotypes, which were obtained from sequence
alignment files provided by the 1000 Genomes Project
pilot3 study. The original files include exonic genotype
data for 3,205 genes and 24,487 SNPs. Eight multilineal
pedigrees are provided and include 697 individuals, all of
whom are genotyped. For each of the 697 individuals, we
are also provided with information on affection status,
age, sex, smoking status, and three quantitative trait vari-
ables called Q1, Q2, and Q4. According to the answers
provided by the GAW17 data simulators, disease risk is
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Q4 and indirectly by sex through Q4. There are 200
replicates of the phenotype data variables; genotype data
are constant over the 200 replicates.
Subjects and linkage subset of markers
We split the pedigrees into 23 unilineal pedigrees with
the intent to include as many individuals in a pedigree as
possible. Because multiple genes were known to contri-
bute to the disease phenotype, we split pedigrees to
reduce intrafamilial genetic heterogeneity. No duplication
of individuals was allowed; parents of some individuals
were set to zero to break links. After splitting, our data
set for each replicate contained 648 individuals. We
determined a linkage subset of markers on the basis of
marker heterozygosity (minimum heterozygosity = 0.1)
and linkage disequilibrium (minimum r
2 = 0.16). Hetero-
zygosity was calculated as 1 − (p
2 + q
2), where p is the
major allele frequency and q is the minor allele fre-
quency. We calculated linkage disequilibrium between all
pairs of markers in pedigree founders using PLINK [2]
and a 100-Mb window.
Weighting of case subjects and linkage model
Our outcome phenotype was affection status. Based on
the GAW17 answers, we performed a logistic regression
analysis and included as predictors of affection status
Age, Sex, Smoking status, and the three quantitative vari-
ables. Using the generated predictive probabilities from
the logistic regression model, we correctly predicted
affection status for approximately 90% of the case sub-
jects (depending on the replicate) using a cut point of
0.5. By graphing the predicted probabilities, we divided
case subjects and control subjects into four quadrants
based on case and control status and predictive probabil-
ity (<0.5 or ≥0.5). Liability classes for the linkage analysis
were divided into these four categories. Control subjects
with low predictive probability (low environmental
scores) and case subjects with high predictive probability
(high environmental scores) were assigned a weaker
penetrance function. Control subjects with high predic-
tive probability (high environmental scores), which we
call high-covariate control subjects, and case subjects
with low predictive probability (low environmental
scores), which we call low-covariate case subjects, were
assigned a more powerful penetrance function.
We performed a parametric model-based analysis using
general dominant and recessive models. For the domi-
nant model, we used a minor allele frequency of 0.01; for
carriers of 0, 1, or 2 copies of the rare allele, the weaker
penetrance function was set to be 0.2, 0.6, 0.6, respec-
tively, and the more powerful penetrance function was
set to be 0.0005, 0.5, 0.5, respectively. For the recessive
model, we used a minor allele frequency of 0.01; for
carriers of 0, 1, or 2 copies of the rare allele, the weaker
penetrance function was set to be 0.2, 0.2, 0.6, respec-
tively, and the more powerful penetrance function was
set to be 0.0005, 0.0005, 0.5, respectively.
Linkage analysis
Linkage analysis was performed using the multipoint
Markov chain Monte Carlo linkage method MCLINK [3],
which allows for multipoint linkage analysis of large
extended pedigrees. Linkage results for MCLINK have
been shown previously to produce similar results to other
linkage packages [4]. Because the phenotype is known to
be attributable to multiple different genes, we report het-
erogeneity LOD (HLOD) scores. MCLINK also provides
information on the most likely haplotype configuration
from the observed data; we assumed that the haplotype of
interest was the haplotype carried by the greatest number
of case subjects in a linked pedigree. We estimated allele
frequencies from observation of genotype data from all
individuals. For the genetic map, we assumed that 1 Mb
was equivalent to 1 cM. This simple assumption has been
shown to produce linkage results that are generally identi-
cal with a more detailed genetic map [5]. To generate suf-
ficient power to detect linkage evidence, we summed the
HLOD scores for the 23 pedigrees across 10 replicates of
data. Each linkage analysis data replicate was completed as
described earlier. We used the Lander and Kruglyak cri-
teria to determine significant (HLOD > 3.3) and suggestive
(HLOD > 1.86) evidence for linkage [6]. Pedigrees linked
to a region of interest were defined as having nominally
significant linkage evidence if their LOD score was greater
than 0.588, which corresponds to a p-value of 0.05, not
accounting for multiple testing.
Follow-up association testing
After identification of linkage evidence and pedigrees
linked to a region, we performed association testing for
only the subjects in the linked pedigrees, using Genie [7],
a software tool that accounts for the relatedness of sub-
jects using Monte Carlo simulation. A single disease-caus-
ing variant, identified using the GAW17 answers, was
tested in the association analyses. We compared two types
of control samples to the case samples. For the first set of
control samples, we selected all founders in the original
eight pedigrees to serve as population controls. Because
the disease was common in the population, a high percen-
tage of these individuals were case subjects, but use of
their genotype frequencies allowed for a consistent com-
parison group across the various case groups studied,
despite the conservative results that were expected. The
second type of control sample was selected to be, in most
cases, the opposite extreme of the case group. For the sec-
ond group of control samples, all case subjects and control
subjects were selected from the linked pedigrees. Because
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selection resulted in some cell counts being zero. To these
zero cells we added 0.5 in order to calculate an odds ratio.
If the samples were all from different pedigrees, then sig-
nificance was determined using Fisher’s exact test in
PLINK [2]. However, if the selected case subjects or con-
trol subjects were related and there was a cell with a zero
frequency, we were not able to calculate the significance
because Genie [7] does not perform Fisher’s exact test.
Association strategies
We compared nine different strategies for selection of
case subjects for sequencing in the eight linked pedigrees
(see detailed list in Tables 1 and 2). Two of the strategies
focused on age because earlier onset is more likely to be
genetic. Four of the strategies focused on the low-covari-
ate status because subjects in these groups were at
decreased risk for environmental contributions to their
disease and at greater risk for genetic contributions. In
these two subgroups we also examined individuals who
were haplotype carriers. Finally, we looked at three addi-
tional strategies: examining all haplotype carriers, exam-
ining all case subjects, and selecting a random case from
each pedigree. Our intent was to compare selective stra-
tegies, for which case subjects had a stronger genetic
contribution to their disease, with more general strate-
gies, such as selecting all case subjects or a random case
subject from each pedigree.
Comparison of association strategies
Because sample size differed between each of the nine case
selection scenarios explored, we compared odds ratio
effect sizes between the strategies so that the power of
each test would not influence our results. To compute a
benefit-cost ratio for each strategy, we assumed that the
benefit of each strategy was the odds ratio effect size and
that the cost was the total number of subjects genotyped.
For the population control set (Table 1), we included the
cost of the case subjects only; we assumed that the foun-
der control subjects represented a population sample and
that those data would be available publicly. For the oppo-
site extreme matched control subjects (Table 2), we
assumed that both the caseg r o u pa n dt h eo p p o s i t e
extreme control group would need to be genotyped, and
hence both groups were included in the cost calculation.
Results
We identified two regions that met the criteria for sug-
g e s t i v ee v i d e n c eo fl i n k a g e ,a n du s i n gt h eG A W 1 7
answers, we identified one of them as harboring a dis-
ease gene. The linkage peak identified was on chromo-
some 17 between C17S3663 and C17S5325 under a
dominant model; our peak HLOD score was 2.44 at
marker C17S5244. From the answers, we identified a
disease gene, PRKCA, that affected disease liability with
casual variants C17S4578 and C17S4581. Eight pedigrees
out of 230 pedigrees tested (23 split pedigrees across 10
replicates) had individual LOD scores greater than
0.588. Variation existed for C17S4578, but not
C17S4581, across the eight pedigrees. Association test-
ing proceeded for C17S4578 using individuals from the
eight linked pedigrees.
In Table 1 we show the results using the 202 founders
as the reference population, and in Table 2 we give the
results for control subjects selected to be the opposite
extreme of the case samples. Overall, the more selective
strategies (i.e., strategies A–G in the tables) resulted in
greater effect sizes and higher benefit-cost ratios than
the more general strategies (strategies H and I in the
tables). The strategy of selecting the youngest haplo-
type-carrier case per pedigree (strategy A) had the high-
est overall effect size and the highest benefit-cost ratio
in Table 1. In Table 2, selection of all low-covariate hap-
lotype-carrier case subjects and all high-covariate non-
haplotype-carrier control subjects (strategy C) per-
formed best overall in terms of effect size and benefit-
cost ratio. In general, the top three strategies (i.e., haplo-
type carriers selected as being the youngest [A] or as
having low covariates [C] or selection of the youngest
case per pedigree [B]) performed well across one of the
two types of control populations or inheritance models.
We note in particular that the all low-covariate haplo-
type-carrier case subjects (strategy C) performed consis-
tently well across both dominant and recessive models
and both types of control populations.
In general, we observed that the overall benefit-cost
ratio was higher under both a dominant and a recessive
model using the 202 founders as the control population,
because of the increased power obtained using a larger
control group and the additional benefit of not incurring
a cost to genotype the control specimens. However, the
effect size for both the dominant and recessive models
tended to be higher when the opposite extreme control
subjects were used as the comparison group (i.e., results
in Table 2). This is expected because the disease was
common among the 202 population controls.
Discussion and conclusions
Linkage analysis has the benefit of being able to localize
disease genes of interest and to identify which pedigrees
should be studied for follow-up sequencing to find the
disease genes. Here, we examined nine strategies for
selecting subjects for follow-up sequencing. Because
sequencing costs are still relatively expensive, it is
imperative to choose subjects for sequencing who will
most likely carry variants in the disease gene.
We found that all the more selective strategies, such
as selecting subjects based on covariate and haplotype
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Page 3 of 6Table 1 Association analysis for C17S4578 comparing case subjects from 8 linked pedigrees to 202 original pedigree founders
Strategy Case subjects
(n)
Case genotype
counts
a
Control subject genotype
counts
a
Dominant model Recessive model
Effect
size
Benefit-cost
ratio
Effect
size
Benefit-cost
ratio
Strategies focused on age
A. Youngest haplotype-carrier case per pedigree 8 5/1/2 15/100/87 2.27 0.28 20.78
c 2.60
B. Youngest case per pedigree 8 4/4/0 15/100/87 12.1
b,c 1.51 12.47
c 1.56
Strategies focused on low-covariate status
C. All low-covariate haplotype-carrier case subjects 13 7/5/1 15/100/87 9.08
c 0.70 14.54
c 1.12
D. Families with 2+ low-covariate haplotype-carrier case
subjects
9 4/4/1 15/100/87 6.05 0.67 9.97
c 1.11
E. All low-covariate case subjects 16 7/6/3 15/100/87 3.28 0.21 9.7
c 0.61
F. Lowest covariate case subject per pedigree 8 3/4/1 15/100/87 5.3 0.66 7.48
c 0.94
Other strategies
G. All haplotype-carrier case subjects per pedigree 40 10/21/9 15/100/87 2.61 0.07 4.16
c 0.10
H.
All case subjects
81 10/40/31 15/100/87 1.22 0.02 1.76 0.02
I. Random case subject per pedigree 8 0/5/3 15/100/87 1.26 0.16 0 0.00
a The three values are the counts for homozygote rare, heterozygote, and wild-type variants.
b For cells with zero count, we added 0.5 to the cell to compute the odds ratio.
cp < 0.05.
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6Table 2 Association analysis for C17S4578 comparing case subjects to opposite extreme control subjects in eight linked pedigrees
Strategy Case subject genotype
counts
a
Control subject
genotype counts
a
Dominant model Recessive model
Effect
size
Benefit-cost
ratio
Effect
size
Benefit-cost
ratio
Strategies focused on age
A. Youngest haplotype-carrier case subject in each pedigree vs. oldest non-haplotype-carrier
control subject
5/1/2 1/5/2 1 0.06 11.67 0.73
B. Youngest case subject vs. oldest control subject in each pedigree 4/4/0 1/3/4 16.0
b 1.0 7 0.44
Strategies focused on low-covariate status
C. All low-covariate haplotype-carrier case subjects vs. all high-covariate non-haplotype-
carrier control subjects
7/5/1 0/4/6 18
c 0.78 23.3
b,d 1.01
D. Families with 2+ low-covariate haplotype-carrier case subjects vs. all high-covariate non-
haplotype-carrier control subjects
4/4/1 0/4/6 12
c 0.63 16.0
b,d 0.84
E. All low-covariate case subjects vs. all high-covariate control subjects 7/6/3 0/4/7 7.58 0.28 17.1
b,d 0.63
F. Lowest covariate case subject vs. highest covariate control subject per pedigree 3/4/1 0/4/4 7 0.44 5.3 0.33
Other strategies
G. All haplotype-carrier case subjects vs. all non-haplotype-carrier control subjects per
pedigree
10/21/9 7/66/104 4.91
c 0.02 8.1
c 0.04
H. All case subjects vs. all control subjects 10/40/31 10/86/110 1.85
c 0.01 2.76
c 0.01
I. Random case subject vs. random control subject per pedigree 0/5/3 1/2/5 2.78 0.17 0 0.00
a The three values are the counts for homozygote rare, heterozygote, and wild-type variants.
b For cells with zero count, we added 0.5 to the cell to compute the odds ratio.
cp < 0.05.
d Unable to compute significance because of a zero cell, and either case or control subjects or both are related.
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6information, out-performed general strategies of sequen-
cing all case subjects in linked pedigrees or sequencing
a random case subject in linked pedigrees. In the linked
pedigrees many case subjects are sporadic cases. Effect
sizes are increased when more case subjects likely to
have a genetic contribution to their disease are included
in an analysis, but effect sizes are not increased when
more sporadic case subjects are included.
We found that the most consistently reliable strategy
across both dominant and recessive models and across
the two types of control groups was selection of haplo-
type carriers who were classified as low-covariate (strat-
egy C) from regression analysis. For this GAW17
analysis, the data simulators provided us with the covari-
ate risk factors for the disease. It was our intent to find
subjects who had the disease but whose disease was more
likely attributable to genetic causes. This strategy can be
applied to many complex diseases. Although all risk fac-
tors may not be known for a particular disease, major
risk factors are likely to be known and could be incorpo-
rated into both the linkage model and the subsequent
selection strategy for identification of sequencing candi-
dates. We also saw good success with selection of the
youngest haplotype-carrier case subject or the youngest
case subject per pedigree. Use of early-onset case subjects
as a surrogate for the low-covariate strategy may be use-
ful when major risk factors for a disease are not known.
In this study, we also explored two types of control
groups: founders from the original pedigrees, which
represented population controls, and control subjects
selected as being the opposite extreme of the case sub-
jects. We found that the benefit-cost ratio was higher, in
general, across both dominant and recessive models for
the population control group than for the model in
which control subjects were selected to be the opposite
extreme of case subjects. The assumption that population
control data can be obtained in the future without cost is
reasonable, because genotype data can be obtained freely
now for various cohorts (e.g., Illumina iControl data and
soon the 1000 Genomes Project). However, it should be
noted that if a disease is common in the population,
results using publicly available sequence data will be
conservative.
We identified two linkage peaks that had suggestive
evidence of linkage, only one of which contained a var-
iant of interest. Suggestive evidence is defined as a LOD
score expected once per chance per genome scan [6].
Hence finding a suggestive linkage result that turns out
to be a false-positive result is within expectation.
In conclusion, choosing case subjects for sequencing
based on being a haplotype carrier and having low-cov-
ariate status can be reliable and cost-effective.
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